Safety and efficacy of favipiravir and camostat mesilate in patients with COVID-19.

Phase 2

• Conditions: Coronavirus; COVID-19

• Registration Number: JPRN-jRCTs031200436
• Lead Sponsor: Yutaka Tokue

Brief Summary

It was a registration of a small number of cases and did not lead to a statistical examination.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-23
• Study Completion: 2021-07-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1) SARS-CoV-2 test positive
2) diagnosed with COVID-19
3) fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan
4) hospital admission
6) patients who have given written consent to participate in the study

Exclusion Criteria

1) pregnancy
2) lactation
3) Women who are not able to give informed consent regarding contraception and using contraceptive divices from the initiation of favipiravir to 14 days after the end of its administration. Men or their partners who are not able to give informed consent regarding contraception and using contraceptive divices from the initiation of favipiravir to 10 days after the end of its administration.

Study & Design

• Study Type: Interventional
• Study Design: Not specified